MedPath

Feasibility trial of UFT after withdrawal of adjuvant TS-1 with adverse effects in patients with curatively resected gastric cancer.

Not Applicable
Suspended
Conditions
Gastric Cancer
Registration Number
JPRN-UMIN000001148
Lead Sponsor
Division of Gastrointestinal Surgery, Kobe University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Suspended
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

administration contraindication of UFT Severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, regular use of insulin or uncontrollable diabetes mellitus, arrhythmias, heart failure, liver cirrhosis, and active hepatitis) Severe watery diarrhea. HIV+ Exclude the patients who are recognized as inadequate patients by doctors with responsibility in this trial.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Feasibility
Secondary Outcome Measures
NameTimeMethod
Safety of UFT Relapse-Free Survival Overall Survival
© Copyright 2025. All Rights Reserved by MedPath